688235 百济神州
已收盘 02-05 15:00:01
资讯
新帖
简况
百济神州（688235）披露证券变动月报表，2月5日股价下跌0.73%
证券之星 · 02-05 22:30
百济神州（688235）披露证券变动月报表，2月5日股价下跌0.73%
每周股票复盘：百济神州（688235）授出273,442股普通股受限制股份单位
证券之星 · 02-01
每周股票复盘：百济神州（688235）授出273,442股普通股受限制股份单位
百济神州(06160)授出涉及2.1万股美国存托股份的受限制股份单位
智通财经网 · 01-30
百济神州(06160)授出涉及2.1万股美国存托股份的受限制股份单位
中国上市、全球首发！百济神州这一创新药开启血液肿瘤治疗新篇章
上观新闻 · 01-28
中国上市、全球首发！百济神州这一创新药开启血液肿瘤治疗新篇章
博时基金万琼旗下博时恒生医疗保健ETF年报最新持仓，重仓百济神州
证券之星 · 01-22
博时基金万琼旗下博时恒生医疗保健ETF年报最新持仓，重仓百济神州
中金港股通与恒指调整预览：紫金黄金国际(02259)等有望纳入恒指 预计44只公司有望入港股通
智通财经 · 01-19
中金港股通与恒指调整预览：紫金黄金国际(02259)等有望纳入恒指 预计44只公司有望入港股通
百济神州：百悦达 在中国商业化上市，惠及中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤及套细胞淋巴瘤成人患者
财经网 · 01-15
百济神州：百悦达 在中国商业化上市，惠及中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤及套细胞淋巴瘤成人患者
百济神州(06160.HK)高开逾3%
每日经济新闻 · 01-14
百济神州(06160.HK)高开逾3%
港股异动 | 百济神州(06160)高开逾3% 宣布百悦达®在中国商业化上市 首批药品将覆盖全国70个城市
智通财经 · 01-14
港股异动 | 百济神州(06160)高开逾3% 宣布百悦达®在中国商业化上市 首批药品将覆盖全国70个城市
百济神州：伯恩斯坦上调评级至跑赢大市，目标价升至414美元
美股速递 · 01-12
百济神州：伯恩斯坦上调评级至跑赢大市，目标价升至414美元
每周股票复盘：百济神州（688235）授出693,186股普通股受限制股份单位
证券之星 · 01-11
每周股票复盘：百济神州（688235）授出693,186股普通股受限制股份单位
美股内部交易 | 百济神州于1月9日披露4笔公司内部人交易情况
同花顺iNews · 01-10
美股内部交易 | 百济神州于1月9日披露4笔公司内部人交易情况
百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位
智通财经 · 01-07
百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位
百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可
老虎资讯综合 · 01-06
百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可
百济神州BCL-2抑制剂“索托克拉”获批上市
医药魔方Info · 01-05
百济神州BCL-2抑制剂“索托克拉”获批上市
加拿大卫生部批准Tevimbra®（注射用Tislelizumab）与吉西他滨和顺铂联合用于成人复发性或转移性鼻咽癌的首选治疗
美股速递 · 2025-12-23
加拿大卫生部批准Tevimbra®（注射用Tislelizumab）与吉西他滨和顺铂联合用于成人复发性或转移性鼻咽癌的首选治疗
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
时代财经 · 2025-12-22
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
双总裁时代的百济神州 还有哪些故事可讲？
国际金融报 · 2025-12-19
双总裁时代的百济神州 还有哪些故事可讲？
百济神州（688235）披露聘任公司高级管理人员公告，12月19日股价上涨0.86%
证券之星 · 2025-12-19
百济神州（688235）披露聘任公司高级管理人员公告，12月19日股价上涨0.86%
63岁吴晓滨离任百济神州总裁，48岁汪来接任
经济观察网 · 2025-12-19
63岁吴晓滨离任百济神州总裁，48岁汪来接任
加载更多
公司概况
公司名称：
百济神州有限公司
所属行业：
医药制造业
上市日期：
2021-12-15
主营业务：
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。
发行价格：
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":275.6,"timestamp":1770274801000,"preClose":277.63,"halted":0,"volume":1980040,"delay":0,"changeRate":-0.0073,"floatShares":114999999,"shares":1541000000,"eps":-0.0994,"marketStatus":"已收盘","change":-2.03,"latestTime":"02-05 15:00:01","open":277.06,"high":279.79,"low":273.13,"amount":545000000,"amplitude":0.024,"askPrice":275.61,"askSize":10,"bidPrice":275.6,"bidSize":21,"shortable":0,"etf":0,"ttmEps":-0.0994,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770341400000},"marketStatusCode":5,"adr":0,"adjPreClose":277.63,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770255000000,1770262200000],[1770267600000,1770274800000]],"highLimit":305.39,"lowLimit":249.87,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1540677809,"isCdr":false,"pbRate":14.47,"roa":"--","roe":"4.26%","epsLYR":-3.64,"committee":-0.57513,"marketValue":424610999999.9999,"turnoverRate":0.0172,"status":1,"afterMarket":{"amount":0,"volume":0,"close":275.6,"buyVolume":0,"sellVolume":0,"time":1770276837558,"indexStatus":"已收盘 02-05 15:30:00","preClose":277.63},"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":209.6,"timestamp":1770278908006,"preClose":211.6,"halted":0,"volume":4453511,"delay":0,"premium":"-32.50"},"floatMarketCap":31709000000},"requestUrl":"/m/hq/s/688235","defaultTab":"news","newsList":[{"id":"2609309272","title":"百济神州（688235）披露证券变动月报表，2月5日股价下跌0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609309272?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:30","pubTimestamp":1770301839,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，百济神州报收于275.6元，较前一交易日下跌0.73%，最新总市值为4246.11亿元。该股当日开盘277.06元，最高279.79元，最低273.13元，成交额达5.45亿元，换手率为1.72%。近日，百济神州有限公司发布证券变动月报表。公告同时确认公众持股量符合上市规则要求，所有证券发行均已获董事会批准并合规进行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06160","BK1500","LU0588546209.SGD","LU2328871848.SGD","BK1588","LU1719994722.HKD","LU1251922891.USD","LU1969619763.USD","161027","BK1161","BK0239","LU1770034418.SGD","688235","BK1583","LU0307460666.USD","LU1303224171.USD"],"gpt_icon":0},{"id":"2608072455","title":"每周股票复盘：百济神州（688235）授出273,442股普通股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072455?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:43","pubTimestamp":1769881393,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，百济神州报收于277.26元，较上周的289.38元下跌4.19%。本周，百济神州1月29日盘中最高价报292.0元。1月30日盘中最低价报277.12元。百济神州当前最新总市值4271.68亿元，在化学制药板块市值排名1/150，在两市A股市值排名29/5184。授出代价为零，无表现目标及退扣机制。该等单位将在未来四年分批归属，每次归属25%，须持续服务。本次授出后，2016期权及激励计划尚余60,920,391股股份可供授出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1770034418.SGD","BK1583","LU1719994722.HKD","LU1969619763.USD","LU0588546209.SGD","BK1588","06160","LU1251922891.USD","LU1303224171.USD","BK1161","688235","LU2328871848.SGD","BK0239","BK1500","LU0307460666.USD"],"gpt_icon":0},{"id":"2607018875","title":"百济神州(06160)授出涉及2.1万股美国存托股份的受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2607018875","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607018875?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:54","pubTimestamp":1769763247,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年1月23 日，董事会薪酬委员会根据2016期权及激励计划的条款向二百四十六名承授人授出涉及合共2.1万股美国存托股份的受限制股份单位。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1303224171.USD","BK0239","BK4585","BK1588","LU0588546209.SGD","LU1719994722.HKD","688235","BK1583","06160","BK1161","BK4139","LU1251922891.USD","LU1969619763.USD","LU2328871848.SGD","BK4526","BK1500","LU0307460666.USD","ONC","LU1770034418.SGD"],"gpt_icon":0},{"id":"2606979167","title":"中国上市、全球首发！百济神州这一创新药开启血液肿瘤治疗新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2606979167","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606979167?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:17","pubTimestamp":1769591825,"startTime":"0","endTime":"0","summary":"百济神州新型BCL2抑制剂索托克拉（百悦达）中国上市会暨全球首发盛典日前举行。会上，众多专家共同就国内慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）以及套细胞淋巴瘤（MCL）的诊疗现状、治疗策略及创新诊疗格局展开分享与讨论，以期推动创新药物更好地造福国内患者。近年来，我国血液肿瘤的防治依然面临严峻挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601283633690762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06078","06978","LU0329678170.USD","LU1770034418.SGD","LU0329678337.USD","BK1500","LU1719994722.HKD","LU1303224171.USD","BK0239","LU2488822045.USD","ONC","BK1583","BK4139","06160","BK4526","BK4585","LU1251922891.USD","BK1161","LU0588546209.SGD","LU1969619763.USD","159992","LU2328871848.SGD","LU0307460666.USD","BK1574","BK1209","688235","BK1588","LU0737861772.HKD"],"gpt_icon":0},{"id":"2605431613","title":"博时基金万琼旗下博时恒生医疗保健ETF年报最新持仓，重仓百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2605431613","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605431613?lang=zh_cn&edition=full","pubTime":"2026-01-22 07:18","pubTimestamp":1769037484,"startTime":"0","endTime":"0","summary":"证券之星消息，1月22日博时基金旗下万琼管理的博时恒生医疗保健交易型开放式指数基金(QDII)公布年报，近1年净值增长率72.87%。与上一季度相比，该基金前十大重仓股新增翰森制药；其中百济神州持仓占比9.71%，为该基金第一大重仓股；阿里健康等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"61e778919a4dfe506392481497ed8680","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200004522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159506","LU0307460666.USD","LU1303224171.USD","688235","BK1500","BK1588","LU0588546209.SGD","LU1770034418.SGD","LU1251922891.USD","BK1583","LU1719994722.HKD","BK1161","LU2328871848.SGD","06160","LU1969619763.USD","BK0239"],"gpt_icon":0},{"id":"2604900915","title":"中金港股通与恒指调整预览：紫金黄金国际(02259)等有望纳入恒指 预计44只公司有望入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2604900915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604900915?lang=zh_cn&edition=full","pubTime":"2026-01-19 14:03","pubTimestamp":1768802591,"startTime":"0","endTime":"0","summary":"考虑到恒生指数编算细则中明确指出，恒指将保留至少20只被认定为香港公司的成分股，此数目至少每两年检讨一次，不排除此次会“递补”其他香港公司进入恒生指数的可能。港股通调整：预计44只有望入通；25只或被移出此次也适逢恒生综合指数的年度审议。此外，部分公司预计分别将于1月28日与2月10日从港交所退市，届时也将被移出港股通交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SGXZ62798434.SGD","YUMC","ONC","SGXZ86797644.SGD","601601","MCHmain","02259","BK4614","06160","09987","BK1198","LU2213484517.USD","HHImain","02328","HK0000500386.USD","02833","LU0593848301.USD","09926","02601","688235","HK0000252160.HKD","LU2543165471.USD","06181","513600","HK0000252152.HKD"],"gpt_icon":1},{"id":"2603765176","title":"百济神州：百悦达 在中国商业化上市，惠及中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤及套细胞淋巴瘤成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2603765176","media":"财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603765176?lang=zh_cn&edition=full","pubTime":"2026-01-15 14:32","pubTimestamp":1768458720,"startTime":"0","endTime":"0","summary":"近日，百济神州发布公告称，依托百济神州研发、生产、商业化全链自主优势，百悦达 在获批8天后迅速实现商业化供应并投入临床使用，惠及中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤及套细胞淋 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260115/c674037106.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260115/c674037106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2603576836","title":"百济神州(06160.HK)高开逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576836","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603576836?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:36","pubTimestamp":1768354599,"startTime":"0","endTime":"0","summary":"每经AI快讯，百济神州(06160.HK)高开逾3%，截至发稿涨3.33%，报210.8港元，成交额1678.72万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143618443468.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143618443468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1303224171.USD","BK1500","BK1583","BK4585","BK1161","BK4526","BK1588","LU1969619763.USD","LU1251922891.USD","BK0239","06160","688235","LU2328871848.SGD","LU0588546209.SGD","LU1770034418.SGD","BK4139","ONC","LU1719994722.HKD","LU0307460666.USD"],"gpt_icon":0},{"id":"2603652978","title":"港股异动 | 百济神州(06160)高开逾3% 宣布百悦达®在中国商业化上市 首批药品将覆盖全国70个城市","url":"https://stock-news.laohu8.com/highlight/detail?id=2603652978","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603652978?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:30","pubTimestamp":1768354233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州高开逾3%，截至发稿，涨3.33%，报210.8港元，成交额1678.72万港元。消息面上，1月14日，据百济神州官微消息，公司宣布其自主研发的1类新药新型BCL2抑制剂百悦达已于1月13日启动供应，首批药品将覆盖全国70个城市。研究结果证实，在经治CLL/SLL及R/R MCL患者中，索托克拉显示出具有临床意义的缓解获益，同时整体耐受性与安全性良好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1770034418.SGD","BK1500","LU1719994722.HKD","LU1303224171.USD","BK0239","ONC","BK1583","BK4139","06160","BK4526","BK4585","LU1251922891.USD","BK1161","LU0588546209.SGD","LU2328871848.SGD","LU0307460666.USD","688235","BK1588","LU1969619763.USD"],"gpt_icon":0},{"id":"1155268538","title":"百济神州：伯恩斯坦上调评级至跑赢大市，目标价升至414美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155268538","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155268538?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:21","pubTimestamp":1768216910,"startTime":"0","endTime":"0","summary":"伯恩斯坦研究机构宣布，将百济神州的投资评级从\"与大市同步\"提升至\"跑赢大市\"，同时将其目标股价从362美元大幅上调至414美元。这一调整反映了该机构对百济神州未来发展前景的积极预期。\n此次评级上调基于对公司核心业务增长潜力的重新评估，目标价的上调幅度达到14.4%，显示出分析师对该公司价值的认可。伯恩斯坦认为，百济神州在创新药物研发和商业化方面展现出的优势，有望推动其业绩实现超预期表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0239","ONC","BK4526","BK4585","688235"],"gpt_icon":0},{"id":"2602533143","title":"每周股票复盘：百济神州（688235）授出693,186股普通股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2602533143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602533143?lang=zh_cn&edition=full","pubTime":"2026-01-11 01:52","pubTimestamp":1768067531,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，百济神州报收于312.99元，较上周的268.6元上涨16.53%。本周，百济神州1月9日盘中最高价报317.84元。百济神州有限公司截至2025年12月31日，法定注册资本为231,146.38美元，已发行普通股总数为1,425,622,549股，另在上海科创板上市人民币股份115,055,260股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1719994722.HKD","LU0588546209.SGD","BK1583","BK1161","BK0239","688235","BK1500","LU1303224171.USD","LU1770034418.SGD","LU1251922891.USD","LU0307460666.USD","LU1969619763.USD","06160","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2602307981","title":"美股内部交易 | 百济神州于1月9日披露4笔公司内部人交易情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2602307981","media":"同花顺iNews","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602307981?lang=zh_cn&edition=full","pubTime":"2026-01-10 08:00","pubTimestamp":1768003200,"startTime":"0","endTime":"0","summary":"2026年1月9日， 百济神州（ONC）披露4笔公司内部人交易情况。高管Lee Chan Henry于2026年1月7日卖出664股。【近期内部交易】披露日期职位姓名交易日期买/卖数量每股成交价/美元总金额/美元2 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20260110/c673908974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2601787308","title":"百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2601787308","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601787308?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:49","pubTimestamp":1767775792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年12月31日，董事会及╱或董事会薪酬委员会根据2016期权及激励计划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制股份单位相当于69.32万股股份，约占本公告之日公司发行股份总数的0.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","LU1251922891.USD","LU1770034418.SGD","BK4526","LU0307460666.USD","BK1500","BK1583","LU1303224171.USD","06160","BK4585","LU2328871848.SGD","BK1161","BK4139","LU0588546209.SGD","BK0239","LU1719994722.HKD","LU1969619763.USD","BK1588","ONC"],"gpt_icon":0},{"id":"1170001608","title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1170001608","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170001608?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:02","pubTimestamp":1767697320,"startTime":"0","endTime":"0","summary":"1月6日，$百济神州$宣布，其自研的1类新药新型BCL2抑制剂百悦达获得国家药品监督管理局附条件批准，用于治疗既往接受过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤成人患者，以及既往接受过至少两种系统性治疗的复发或难治性套细胞淋巴瘤成人患者。基于此次获批，索托克拉将为已接受过BTK抑制剂治疗的CLL/SLL患者带来新的治疗选择，更使其成为国内首款且唯一可用于治疗MCL的BCL2抑制剂。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK4139","ONC","LU1969619763.USD","BK4526","BK1500","LU1251922891.USD","LU1719994722.HKD","BK1583","BK1161","BK0239","LU1770034418.SGD","LU0307460666.USD","06160","BK1588","LU0588546209.SGD","LU1303224171.USD","LU2328871848.SGD","BK4585"],"gpt_icon":0},{"id":"2601800005","title":"百济神州BCL-2抑制剂“索托克拉”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601800005","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601800005?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:19","pubTimestamp":1767608340,"startTime":"0","endTime":"0","summary":"1 月 5日，NMPA 官网显示，百济神州BCL-2抑制剂“索托克拉”两项适应症中国获批上市，适用于治疗既往接受过治疗的慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤成人患者，以及治疗既往接受过抗CD20治疗和BTKi治疗的套细胞淋巴瘤成人患者。索托克拉是百济神州开发的一款强效、高选择性BCL-2抑制剂，其设计旨在产生更深、更持久的靶点抑制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-01-05/doc-inhfhavn6767115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1303224171.USD","BK0239","BK4585","BK1588","LU0588546209.SGD","LU1719994722.HKD","688235","BK1583","06160","BK1161","BK4139","LU1251922891.USD","LU1969619763.USD","LU2328871848.SGD","BK4526","BK1500","LU0307460666.USD","ONC","LU1770034418.SGD"],"gpt_icon":0},{"id":"1147294652","title":"加拿大卫生部批准Tevimbra®（注射用Tislelizumab）与吉西他滨和顺铂联合用于成人复发性或转移性鼻咽癌的首选治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1147294652","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147294652?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:04","pubTimestamp":1766495093,"startTime":"0","endTime":"0","summary":"加拿大卫生部已批准Tevimbra®（注射用Tislelizumab）与吉西他滨和顺铂联用，作为成人复发性或转移性鼻咽癌的首选治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2593483856","title":"获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483856","media":"时代财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483856?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:58","pubTimestamp":1766393880,"startTime":"0","endTime":"0","summary":"12月21日晚间，加科思药业（01167.HK）宣布，已就其自主研发的泛KRAS（Pan-KRAS）抑制剂 JAB-23E73与阿斯利康（AZN.US）达成合作协议。根据协议，阿斯利康将获得该产品在中国以外市场的独家 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251222/c673401182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU1064130708.USD","LU1064131003.USD","LU2488822045.USD","688428","688235","BK0239","688331","LU2148510915.USD"],"gpt_icon":0},{"id":"2592959471","title":"双总裁时代的百济神州 还有哪些故事可讲？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592959471","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592959471?lang=zh_cn&edition=full","pubTime":"2025-12-19 23:31","pubTimestamp":1766158317,"startTime":"0","endTime":"0","summary":"12月19日，百济神州迎来新的人事调整。百济神州发布公告称，公司董事会同意聘任全球研发负责人汪来博士担任百济神州总裁，全球研发负责人。聘任生效后，汪来将担任百济神州总裁，全球研发负责人职务，负责管理百济神州研发、业务拓展以及业务联盟关系管理等职能。此外，百济神州方面还透露，吴晓滨仍然担任百济神州总裁、首席运营官COO，与汪来并列为双总裁。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193597095415.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193597095415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1588","BK4526","LU1770034418.SGD","LU0588546209.SGD","LU1969619763.USD","LU2328871848.SGD","BK4139","06160","LU1719994722.HKD","BK4585","BK1500","BK0239","LU1303224171.USD","LU0307460666.USD","BK1583","LU1251922891.USD","688235","ONC"],"gpt_icon":0},{"id":"2592150459","title":"百济神州（688235）披露聘任公司高级管理人员公告，12月19日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592150459","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592150459?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:43","pubTimestamp":1766137421,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，百济神州报收于274.0元，较前一交易日上涨0.86%，最新总市值为4221.46亿元。该股当日开盘272.0元，最高274.88元，最低269.79元，成交额达4.9亿元，换手率为1.56%。公司近日发布公告称，2025年12月17日，经公司董事会审议通过，聘任汪来博士担任百济神州有限公司总裁、全球研发负责人，负责管理公司研发、业务拓展及业务联盟关系管理等职能。汪来博士自2011年加入公司，曾任多个研发领导职务，2021年4月起任全球研发负责人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900027078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1251922891.USD","BK1161","688235","BK1583","LU0588546209.SGD","BK1500","LU1719994722.HKD","LU1969619763.USD","LU0307460666.USD","LU1303224171.USD","LU1770034418.SGD","06160","BK0239","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2592136978","title":"63岁吴晓滨离任百济神州总裁，48岁汪来接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2592136978","media":"经济观察网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592136978?lang=zh_cn&edition=full","pubTime":"2025-12-19 09:33","pubTimestamp":1766107980,"startTime":"0","endTime":"0","summary":"经济观察报 记者 张铃12月18日晚，百济神州（688235.SH/06160.HK/ONC.US）公告，聘任汪来担任总裁、全球研发负责人，负责管理研发、业务拓展以及业务联盟关系管理等职能。在2026年1月1日生 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251219/c673339845.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251219/c673339845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688235","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770321816407,"stockEarnings":[{"period":"1week","weight":-0.0356},{"period":"1month","weight":-0.0773},{"period":"3month","weight":-0.0122},{"period":"6month","weight":0.2269},{"period":"1year","weight":0.429},{"period":"ytd","weight":0.0261}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":-0.0019},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.2621},{"period":"ytd","weight":0.027}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36008人(较上一季度增加55.74%)","perCapita":"3195股","listingDate":"2021-12-15","address":"c/oBeOneMedicinesIGmbH,Aeschengraben27,4051Basel,Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","listedPrice":192.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}